JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Exploring the Effect of Fidgetin-Like 1 on Colorectal Cancer Through Tissue Chip and In Vitro Experiments

  • 0Clinic of Central Laboratory, Hai’an City People’s Hospital of Jiangsu Province, Hai’an Hospital Affiliated to Nantong University, Nantong, China
Balkan Medical Journal +

|

September 25, 2024

|

September 25, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Fidgetin-like 1 (FIGNL1) promotes colorectal cancer (CRC) cell growth and spread. Inhibiting FIGNL1 may offer a new strategy for treating CRC patients.

Area Of Science

  • Oncology
  • Molecular Biology
  • Cancer Research

Background

  • Fidgetin-like 1 (FIGNL1) is overexpressed in various cancers, linked to poor prognosis in renal clear-cell carcinoma, gliomas, and hepatocellular carcinoma.
  • Its role in colorectal cancer (CRC) remains largely uncharacterized.

Purpose Of The Study

  • To investigate the function of FIGNL1 in colorectal cancer (CRC).

Main Methods

  • Utilized TCGA database and immunohistochemistry to assess FIGNL1 expression in CRC tissues.
  • Employed cell viability, migration, and invasion assays to evaluate FIGNL1's functional impact.
  • Used siRNA and lentivirus for FIGNL1 knockdown and overexpression, respectively, and STRING database for protein interaction prediction.

Main Results

  • FIGNL1 is upregulated in CRC tissues and correlates with advanced TNM stages and lymph node metastasis.
  • Silencing FIGNL1 inhibited CRC cell proliferation, migration, and invasion.
  • Overexpression of FIGNL1 promoted CRC cell proliferation, migration, and invasion through P38 signaling pathway activation, dependent on SPIDR interaction.

Conclusions

  • FIGNL1 plays a significant role in CRC progression.
  • FIGNL1 represents a potential therapeutic target for colorectal cancer treatment.